Impact of Phosphodiesterase-3 Inhibitor and Prostacyclin Analogue Combination on Pulmonary Hemodynamics in Acyanotic Congenital Heart Disease Patients with Pulmonary Hypertension: A Randomized Controlled Trial

Impact of Phosphodiesterase-3 Inhibitor and Prostacyclin Analogue Combination on Pulmonary Hemodynamics in Acyanotic Congenital Heart Disease Patients with Pulmonary Hypertension: A Randomized Controlled Trial

Background: Acyanotic congenital heart disease (ACHD) with left-to-right shunting frequently presents with pulmonary hypertension (PH), especially in developing countries where treatment options are often limited and costly. Cilostazol, a phosphodiesterase-3 inhibitor, has vasodilatory and inotropic...

Full description

Saved in:
Bibliographic Details
Main Authors: Sefri Noventi Sofia, Bahrudin, Ignatius Riwanto, Anindita Soetadji, Hardhono, Muhammad Thifan Satyagraha
Format: Article
Language:English
Published: International Medical Research and Development Corporation 2025-06-01
Series:International Journal of Biomedicine
Subjects:
congenital heart disease
pulmonary hypertension
phosphodiesterase inhibitor
prostacyclin analogue
Online Access:http://www.ijbm.org/articles/i58/ijbm_15(2)_oa1.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.ijbm.org/articles/i58/ijbm_15(2)_oa1.pdf

Similar Items